Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.

Furuta T, Yamade M, Kagami T, Uotani T, Suzuki T, Higuchi T, Tani S, Hamaya Y, Iwaizumi M, Miyajima H, Umemura K, Osawa S, Sugimoto K.

Digestion. 2019 Aug 21:1-9. doi: 10.1159/000502287. [Epub ahead of print]

PMID:
31434101
2.

Decompressive laparotomy for abdominal compartment syndrome resulting from severe acute pancreatitis: a case report.

Ikeda S, Kagami T, Tani S, Uotani T, Yamade M, Hamaya Y, Morita Y, Sakaguchi T, Osawa S, Sugimoto K.

BMC Gastroenterol. 2019 Aug 8;19(1):141. doi: 10.1186/s12876-019-1059-0.

3.

Evaluating mucosal healing using colon capsule endoscopy predicts outcome in patients with ulcerative colitis in clinical remission.

Takano R, Osawa S, Uotani T, Tani S, Ishida N, Tamura S, Yamade M, Iwaizumi M, Hamaya Y, Furuta T, Miyajima H, Sugimoto K.

World J Clin Cases. 2018 Dec 6;6(15):952-960. doi: 10.12998/wjcc.v6.i15.952.

4.

CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines.

Rajapakse VN, Luna A, Yamade M, Loman L, Varma S, Sunshine M, Iorio F, Sousa FG, Elloumi F, Aladjem MI, Thomas A, Sander C, Kohn KW, Benes CH, Garnett M, Reinhold WC, Pommier Y.

iScience. 2018 Dec 21;10:247-264. doi: 10.1016/j.isci.2018.11.029. Epub 2018 Dec 12.

5.

Prevalence of elevated microsatellite alterations at selected tetranucleotide repeats in pancreatic ductal adenocarcinoma.

Mori T, Hamaya Y, Uotani T, Yamade M, Iwaizumi M, Furuta T, Miyajima H, Osawa S, Sugimoto K.

PLoS One. 2018 Dec 7;13(12):e0208557. doi: 10.1371/journal.pone.0208557. eCollection 2018.

6.

High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy.

Kagami T, Yamade M, Suzuki T, Uotani T, Tani S, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Baba S, Sugimura H, Miyajima H, Furuta T.

Oncotarget. 2018 Oct 9;9(79):34876-34888. doi: 10.18632/oncotarget.26172. eCollection 2018 Oct 9.

7.

High incidence of autoimmune gastritis in patients misdiagnosed with two or more failures of H. pylori eradication.

Furuta T, Baba S, Yamade M, Uotani T, Kagami T, Suzuki T, Tani S, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K.

Aliment Pharmacol Ther. 2018 Aug;48(3):370-377. doi: 10.1111/apt.14849. Epub 2018 Jun 19.

PMID:
29920721
8.

Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin.

Suzuki T, Kagami T, Uotani T, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Furuta T.

Eur J Clin Pharmacol. 2018 Jan;74(1):45-52. doi: 10.1007/s00228-017-2324-1. Epub 2017 Oct 6.

PMID:
28986609
9.

Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype.

Kagami T, Yamade M, Suzuki T, Uotani T, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T.

Clin Pharmacol Ther. 2018 May;103(5):906-913. doi: 10.1002/cpt.863. Epub 2017 Oct 13.

PMID:
28875498
10.

Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel.

Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Sahara S, Ichikawa H, Kagami T, Iwaizumi M, Hamaya Y, Osawa S, Sugimoto K, Umemura K.

J Thromb Thrombolysis. 2017 Apr;43(3):333-342. doi: 10.1007/s11239-016-1460-2.

PMID:
27981489
11.

Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.

Kagami T, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Furuta T.

Aliment Pharmacol Ther. 2016 May;43(10):1048-59. doi: 10.1111/apt.13588. Epub 2016 Mar 18.

12.

One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.

Kagami T, Sugimoto M, Ichikawa H, Sahara S, Uotani T, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Furuta T.

Eur J Clin Pharmacol. 2015 Dec;71(12):1467-75. doi: 10.1007/s00228-015-1941-9. Epub 2015 Oct 2.

PMID:
26427705
13.

Potent Gastric Acid Inhibition Over 24 Hours by 4-Times Daily Dosing of Esomeprazole 20 mg.

Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Kagami T, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Furuta T.

Digestion. 2015;91(4):277-85. doi: 10.1159/000381419. Epub 2015 Apr 28.

PMID:
25924819
14.

SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.

Tang SW, Bilke S, Cao L, Murai J, Sousa FG, Yamade M, Rajapakse V, Varma S, Helman LJ, Khan J, Meltzer PS, Pommier Y.

Clin Cancer Res. 2015 Sep 15;21(18):4184-93. doi: 10.1158/1078-0432.CCR-14-2112. Epub 2015 Mar 16.

15.

Influence of prostate stem cell antigen gene polymorphisms on susceptibility to Helicobacter pylori-associated diseases: a case-control study.

Ichikawa H, Sugimoto M, Uotani T, Sahara S, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Miyajima H, Yamaoka Y, Furuta T.

Helicobacter. 2015 Apr;20(2):106-13. doi: 10.1111/hel.12183. Epub 2015 Jan 12.

PMID:
25582162
16.

Intra-gastric pH following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparison.

Furuta K, Kohata Y, Fujiwara Y, Sugimoto M, Uotani T, Yamade M, Sahara S, Ichikawa H, Furuta T, Nio K, Iwakiri R, Inamori M, Kawamura O, Kusano M, Kato M, Kawami N, Iwakiri K, Takeuchi T, Higuchi K, Aimi M, Naora K, Fujimoto K, Arakawa T, Kinoshita Y.

J Clin Biochem Nutr. 2014 Nov;55(3):178-83. doi: 10.3164/jcbn.14-41. Epub 2014 Oct 4.

17.

Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.

Sugimoto M, Uotani T, Sahara S, Ichikawa H, Yamade M, Sugimoto K, Furuta T.

Helicobacter. 2014 Aug;19(4):312-8. doi: 10.1111/hel.12128. Epub 2014 Apr 1.

PMID:
24690010
18.

Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin.

Furuta T, Sugimoto M, Yamade M, Uotani T, Sahara S, Ichikawa H, Kagami T, Yamada T, Osawa S, Sugimoto K, Watanabe H, Umemura K.

Intern Med. 2014;53(6):571-5.

19.

Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine.

Uotani T, Sugimoto M, Nishino M, Ichikawa H, Sahara S, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Watanabe H, Miyajima H, Furuta T.

J Clin Pharmacol. 2014 Aug;54(8):858-64. doi: 10.1002/jcph.284. Epub 2014 Mar 21.

PMID:
24615745
20.

Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.

Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Sahara S, Ichikawa H, Yamada T, Osawa S, Sugimoto K, Watanabe H, Umemura K.

J Gastroenterol Hepatol. 2014 Mar;29(3):487-93. doi: 10.1111/jgh.12442.

PMID:
24224808
21.

Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy.

Furuta T, Sugimoto M, Yamade M, Uotani T, Sahara S, Ichikawa H, Yamada T, Osawa S, Sugimoto K, Watanabe H, Umemura K.

J Clin Pharmacol. 2014 Mar;54(3):258-66. doi: 10.1002/jcph.195. Epub 2013 Oct 22.

PMID:
24122836
22.

Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.

Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T.

Aliment Pharmacol Ther. 2013 Nov;38(9):1129-37. doi: 10.1111/apt.12492. Epub 2013 Sep 16.

23.

Association of gastric mucosal injury severity with platelet function and gastric pH during low-dose aspirin treatment.

Nishino M, Sugimoto M, Uotani T, Yamade M, Sahara S, Ichikawa H, Sugimoto K, Umemura K, Watanabe H, Miyajima H, Furuta T.

Digestion. 2013;88(2):79-86. doi: 10.1159/000353150. Epub 2013 Aug 9.

PMID:
23941821
24.

Antiplatelet drugs are a risk factor for esophageal mucosal injury.

Sugimoto M, Uotani T, Nishino M, Yamade M, Sahara S, Yamada T, Osawa S, Sugimoto K, Umemura K, Watanabe H, Miyajima H, Furuta T.

Digestion. 2013;87(4):281-9. doi: 10.1159/000350438. Epub 2013 Jun 13.

PMID:
23774797
25.

[Judgment of eradication of H. pylori based on percent changes in serum pepsinogens].

Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Sahara S, Ichikawa H, Yamada T, Sugimoto K, Osawa S, Shirai N.

Nihon Shokakibyo Gakkai Zasshi. 2013 Feb;110(2):210-7. Review. Japanese. No abstract available.

PMID:
23381208
26.

Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype.

Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Yamade M, Sahara S, Ichikawa H, Sugimoto K, Miyajima H, Furuta T.

Aliment Pharmacol Ther. 2012 Oct;36(7):627-34. doi: 10.1111/apt.12014. Epub 2012 Aug 10.

27.

Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype.

Uotani T, Sugimoto M, Nishino M, Kodaira C, Yamade M, Sahara S, Yamada T, Osawa S, Sugimoto K, Tanaka T, Umemura K, Watanabe H, Miyajima H, Furuta T.

Clin Gastroenterol Hepatol. 2012 Aug;10(8):879-885.e2. doi: 10.1016/j.cgh.2012.04.016. Epub 2012 Apr 25.

PMID:
22542748
28.

Trastuzumab has opposing effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence.

Yamade M, Sugimoto M, Nishino M, Uotani T, Sahara S, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Miyajima H, Furuta T.

Anticancer Res. 2012 Jan;32(1):105-14.

PMID:
22213294
29.

Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin.

Sugimoto M, Nishino M, Kodaira C, Yamade M, Uotani T, Ikuma M, Furuta T.

Digestion. 2012;85(1):9-17. doi: 10.1159/000329295. Epub 2011 Nov 24.

PMID:
22122999
30.

Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan.

Yamade M, Sugimoto M, Uotani T, Nishino M, Kodaira C, Furuta T.

J Gastroenterol Hepatol. 2011 Sep;26(9):1457-61. doi: 10.1111/j.1440-1746.2011.06815.x.

PMID:
21679250
31.

Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy.

Sugimoto M, Nishino M, Kodaira C, Yamade M, Uotani T, Ikuma M, Umemura K, Furuta T.

World J Gastroenterol. 2011 Apr 14;17(14):1858-65. doi: 10.3748/wjg.v17.i14.1858.

32.

Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [(13)C]-aminopyrine breath test.

Kodaira C, Uchida S, Yamade M, Nishino M, Ikuma M, Namiki N, Sugimoto M, Watanabe H, Hishida A, Furuta T.

J Clin Pharmacol. 2012 Mar;52(3):432-9. doi: 10.1177/0091270010397728. Epub 2011 Mar 17.

PMID:
21415279
33.

The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori.

Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Ikuma M, Shirai N.

Hepatogastroenterology. 2010 Sep-Oct;57(102-103):1314-9.

PMID:
21410079
34.

[A case of eosinophilic gastroenteritis accompanied with fasciitis of the extremities].

Matsuura T, Yamade M, Matsushita N, Kawasaki S, Terai T, Uotani T, Takayanagi Y, Yamada T, Kodaira C, Sugimoto M, Furuta T, Sugimoto K, Osawa S, Ikuma M.

Nihon Shokakibyo Gakkai Zasshi. 2011 Mar;108(3):444-50. Japanese.

PMID:
21389666
35.

Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers.

Nishino M, Sugimoto M, Kodaira C, Yamade M, Uotani T, Shirai N, Ikuma M, Tanaka T, Sugimura H, Hishida A, Furuta T.

J Clin Pharmacol. 2011 Jul;51(7):1079-86. doi: 10.1177/0091270010376194. Epub 2010 Jul 27.

PMID:
20663999
36.

Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole.

Sugimoto M, Nishino M, Kodaira C, Yamade M, Ikuma M, Tanaka T, Sugimura H, Hishida A, Furuta T.

J Clin Pharmacol. 2010 Mar;50(3):320-30. doi: 10.1177/0091270009344983. Epub 2009 Nov 25.

PMID:
19940233
37.

Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma.

Osawa S, Furuta T, Sugimoto K, Kosugi T, Terai T, Yamade M, Takayanagi Y, Nishino M, Hamaya Y, Kodaira C, Yamada T, Iwaizumi M, Takagaki K, Yoshida K, Kanaoka S, Ikuma M.

BMC Cancer. 2009 Nov 22;9:408. doi: 10.1186/1471-2407-9-408.

38.

Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers.

Nishino M, Sugimoto M, Kodaira C, Yamade M, Shirai N, Ikuma M, Tanaka T, Sugimura H, Hishida A, Furuta T.

Dig Dis Sci. 2010 Jun;55(6):1627-36. doi: 10.1007/s10620-009-0920-3. Epub 2009 Aug 12.

PMID:
19672708
39.

[13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole.

Furuta T, Kodaira C, Nishino M, Yamade M, Sugimoto M, Ikuma M, Hishida A, Watanabe H, Umemura K.

Aliment Pharmacol Ther. 2009 Aug;30(3):294-300. doi: 10.1111/j.1365-2036.2009.04044.x. Epub 2009 May 18.

40.

CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole.

Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Ikuma M, Shirai N, Watanabe H, Umemura K, Kimura M, Hishida A.

Eur J Clin Pharmacol. 2009 Jul;65(7):693-8. doi: 10.1007/s00228-009-0628-5. Epub 2009 Mar 4.

PMID:
19259653
41.

Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects.

Kodaira C, Sugimoto M, Nishino M, Yamade M, Shirai N, Uchida S, Ikuma M, Yamada S, Watanabe H, Hishida A, Furuta T.

Eur J Clin Pharmacol. 2009 Jun;65(6):593-600. doi: 10.1007/s00228-009-0625-8. Epub 2009 Feb 24.

PMID:
19238367
42.

Polymorphisms of matrix metalloproteinase-7 and chymase are associated with susceptibility to and progression of gastric cancer in Japan.

Sugimoto M, Furuta T, Kodaira C, Nishino M, Yamade M, Ikuma M, Sugimura H, Hishida A.

J Gastroenterol. 2008;43(10):751-61. doi: 10.1007/s00535-008-2221-6. Epub 2008 Oct 29.

PMID:
18958543
43.

MDR1 C3435T polymorphism has no influence on developing Helicobacter pylori infection-related gastric cancer and peptic ulcer in Japanese.

Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Yamade M, Ikuma M, Sugimura H, Ishizaki T, Hishida A.

Life Sci. 2008 Aug 15;83(7-8):301-4. doi: 10.1016/j.lfs.2008.06.022. Epub 2008 Jul 3.

PMID:
18644389
44.

Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics.

Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Yamade M, Ikuma M, Watanabe H, Ohashi K, Hishida A, Ishizaki T.

Expert Opin Pharmacother. 2007 Nov;8(16):2701-17. Review.

PMID:
17956193
45.

Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.

Furuta T, Sugimoto M, Shirai N, Matsushita F, Nakajima H, Kumagai J, Senoo K, Kodaira C, Nishino M, Yamade M, Ikuma M, Watanabe H, Umemura K, Ishizaki T, Hishida A.

Aliment Pharmacol Ther. 2007 Sep 1;26(5):693-703.

46.

Personalized medicine for eradication of Helicobacter pylori.

Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Shirai N, Ikuma M, Hishida A, Ishizaki T.

Per Med. 2007 Aug;4(3):321-328. doi: 10.2217/17410541.4.3.321.

PMID:
29788670
47.

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.

Furuta T, Shirai N, Kodaira M, Sugimoto M, Nogaki A, Kuriyama S, Iwaizumi M, Yamade M, Terakawa I, Ohashi K, Ishizaki T, Hishida A.

Clin Pharmacol Ther. 2007 Apr;81(4):521-8. Epub 2007 Jan 10.

PMID:
17215846

Supplemental Content

Loading ...
Support Center